This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Apr 2011

Achillion Reports Positive Results from Hepatitis C Drug Study

The results showed that 75-81% of patients treated with ACH-1625 achieved rapid virologic response with a promising safety and tolerability profile.

Achillion Pharmaceuticals has reported positive top-line results from its ongoing Phase IIa clinical trial which evaluates ACH-1625 in patients with chronic hepatitis C. ACH-1625 is an inhibitor of HCV NS3 protease that was discovered by and is being developed by Achillion.

 

The results showed that 75-81% of patients treated with ACH-1625 achieved rapid virologic response with a promising safety and tolerability profile.

 

In the first stage of a two-segment Phase IIa trial, 64 patients were enrolled and randomised to receive one of three doses of ACH-1625 once-daily (200mg, 400mg or 800mg) or placebo with peginterferon alfa-2a and ribavirin, the current standard of care.

 

Related News